Drug Shortage Report for ERWINASE

Last updated on 2018-03-07 History
Report ID 2952
Drug Identification Number 02237815
Brand name ERWINASE
Common or Proper name Erwinia L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS
Market Status CANCELLED POST MARKET
Active Ingredient(s) ASPARAGINASE
Strength(s) 10000UNIT
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials
ATC code L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2017-03-14
Actual start date
Estimated end date 2017-06-30
Actual end date 2017-06-30
Shortage status Resolved
Updated date 2018-03-07
Company comments Reason for ongoing shortage in Canada (less than 3-months supply) due to global capacity constraints in manufacturing leading to just-in time supply with intermittent shortages. Additionally demand has increased from average of 51 packs per month to 105 packs per month.
Health Canada comments
Contact Address 84 QUAI CHARLES DE GAULLE CITY ONE
LYON, AUVERGNE-RHONE-ALPES
FRANCE 69006
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2018-03-07 English Compare
v7 2017-04-24 French Compare
v6 2017-04-24 English Compare
v5 2017-03-16 French Compare
v4 2017-03-16 English Compare
v3 2017-03-16 English Compare
v2 2017-03-15 French Compare
v1 2017-03-15 English Compare